Rodent models for dry eye syndrome: Standardization using benzalkonium chloride and scopolamine hydrobromide

Chaudhari, Pinal; Satarker, Sairaj; Thomas, Rinu; Theruveethi, Nagarajan; Ghate, Vivek; Nampoothiri, Madhavan; Lewis, Shaila

doi:10.1016/j.lfs.2023.121463

Cited by 6 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…b.i.d. ) for 10 continuous days and confirmed by corneal fluorescein staining and hematoxylin and eosin (H&E) staining. , Then animals were treated with corresponding formulations as eye drops (13 μL, rtt. q.d. )…”

Section: Methodsmentioning

confidence: 99%

Combination of PEGylation and Cationization on Phospholipid-Coated Cyclosporine Nanosuspensions for Enhanced Ocular Drug Delivery

Ma,

Liu,

Wang

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Strong precorneal clearance mechanisms including reflex blink, constant tear drainage, and rapid mucus turnover constitute great challenges for eye drops for effective drug delivery to the ocular epithelium. In this study, cyclosporine A (CsA) for the treatment of dry eye disease (DED) was selected as the model drug. Two strategies, PEGylation for mucus penetration and cationization for potent cellular uptake, were combined to construct a novel CsA nanosuspension (NS@lipid-PEG/CKC) by coating nanoscale drug particles with a mixture of lipids, DSPE-PEG2000, and a cationic surfactant, cetalkonium chloride (CKC). NS@lipid-PEG/CKC with the mean size ∼173 nm and positive zeta potential ∼+40 mV showed promoted mucus penetration, good cytocompatibility, more cellular uptake, and prolonged precorneal retention without obvious ocular irritation. More importantly, NS@lipid-PEG/CKC recovered tear production and goblet cell density more efficiently than the commercial cationic nanoemulsion on a dry eye disease rat model. All results indicated that a combination of PEGylation and cationization might provide a promising strategy to coordinate mucus penetration and cellular uptake for enhanced drug delivery to the ocular epithelium for nanomedicine-based eye drops.

show abstract

Section: Methodsmentioning

confidence: 99%

Combination of PEGylation and Cationization on Phospholipid-Coated Cyclosporine Nanosuspensions for Enhanced Ocular Drug Delivery

Ma,

Liu,

Wang

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Tear secretion condition was assessed by the Schirmer test as previously reported. [ 29 ] On the premise of not touching the eyelid and ocular surface, phenol red thread was inserted in the tear meniscus for 15 s. The length of the wetted thread was measured and recorded.…”

Section: Methodsmentioning

confidence: 99%

Engineering Ultra‐Small Cerium‐Based Metal–Organic Frameworks Nanozymes for Efficient Antioxidative Treatment of Dry Eye Disease

Chen,

Li,

Tang

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Dry eye disease (DED) is a widespread ophthalmic illness that inflicts massive economic and medical burdens on society. Although oxidative stress is closely associated with the onset of DED, barely any quantities of antioxidants are clinically available owing to low efficiency, toxicity, and poor bioavailability. Cerium‐based nanozymes possess promising enzyme‐mimetic activities in scavenging reactive oxygen species (ROS). Moreover, the ultra‐small metal–organic frameworks (MOFs) have the potential for more efficient drug delivery, ROS elimination, and therapeutic efficacy. However, the development of ultra‐small cerium‐based MOFs (Ce‐MOFs) is limited to a small minority due to challenges in the synthetic process and stability. By simply adjusting raw ingredients concentrations, three types of Ce‐MOFs with distinct particle sizes are synthesized: Ce‐MOF 1 (213 nm), Ce‐MOF 2 (36 nm), and Ce‐MOF 3 (2 nm). In comparison, the obtained ultra‐small Ce‐MOF 3 exhibited superior ROS scavenging and antioxidant capacity, decreased cytotoxicity, and excellent ocular penetration. Therapeutically, Ce‐MOF 3 is demonstrated to be highly efficient in alleviating DED by suppressing oxidative stress and inflammation, boosting corneal epithelial repair, and facilitating tear secretion recovery. The novel ultra‐small Ce‐MOF 3 may serve as a promising alternative treatment for DED and other ROS‐related disorders when combined with ocular biocompatibility.

show abstract

Oridonin ameliorates ocular surface inflammatory responses by inhibiting the NLRP3/caspase-1/GSDMD pyroptosis pathway in dry eye

Li,

Chen,

Chen

et al. 2024

Experimental Eye Research

View full text Add to dashboard Cite

Rodent models for dry eye syndrome: Standardization using benzalkonium chloride and scopolamine hydrobromide

Cited by 6 publications

References 34 publications

Combination of PEGylation and Cationization on Phospholipid-Coated Cyclosporine Nanosuspensions for Enhanced Ocular Drug Delivery

Combination of PEGylation and Cationization on Phospholipid-Coated Cyclosporine Nanosuspensions for Enhanced Ocular Drug Delivery

Engineering Ultra‐Small Cerium‐Based Metal–Organic Frameworks Nanozymes for Efficient Antioxidative Treatment of Dry Eye Disease

Oridonin ameliorates ocular surface inflammatory responses by inhibiting the NLRP3/caspase-1/GSDMD pyroptosis pathway in dry eye

Contact Info

Product

Resources

About